[ad_1]
Yas Holding LLC (YHL), an investment group headquartered in the UAE, has completed the acquisition of Gulf Inject LLC (GI) from the Gulf Pharmaceutical Industry Company (Julpha) headquartered in Ras Al Khaimah, a listed pharmaceutical company headquartered in the UAE. The 100% acquisition, including the Jebel Ali Free Zone branch of Gulf Inject, was completed through Yas Holding’s dedicated healthcare investment tool, GlobalOne Healthcare Holding LLC (GHH).
GHH’s healthcare product portfolio includes biopharmaceuticals, manufacturing, medical supply chain, hospital and clinic management, healthcare technology, and occupational health and healthcare.
The acquisition was made in the context of the UAE’s announcement this week that it has the most competitive industrial sector in the Arab world. It will climb five places to the 30th in the world in the UNIDO Competitive Industry Performance Index (CIP) in 2021. Bit) report, tracking 152 countries. Continuous improvement is in line with the UAE’s industrial strategy “300 billion operations”, which aims to develop the country’s industrial sector and enhance its role in stimulating the national economy.
Commenting on the latest acquisition, Mr. Murshed Al Redaini, CEO of Yas Holding Group, said: “Yas Holding is pleased to announce that we have acquired Gulf Inject. Increasing their production facilities is very important to our growing healthcare manufacturing and distribution ecosystem. Strategic value. Through this acquisition, Yas Holdings will continue to fulfill its commitment to improving health outcomes and improving the quality of life of patients.”
Established in 1994, Gulf Inject manufactures and distributes sterile injectable solutions and is a leading company in the field of fluid management therapy in the UAE. GI has a complete production facility in JAFZA, Dubai, and produces 65 products, including injections, intravenous infusions, antibiotics, local anesthetics and hypertonic solutions for the treatment of critically ill and chronically ill patients.
Suresh Vaidhyanathan, Chief Financial Officer of Yas Holding Group, said: “This acquisition aims to generate multiple synergies and together position GHH as the region’s leading healthcare investment company. The transaction further strengthens Yas Holding’s position as a leading investor in the local manufacturing industry. Aspirations of the United Arab Emirates to align with the UAE’s long-term strategic goals.”
Ashraf Radwan, CEO of GlobalOne Healthcare, explained: “Combined with GHH’s Wellpharma Medical Solutions (WMS), this acquisition will enable GHH to occupy a market leading position in providing domestic intravenous infusions and rank among the top three in the Middle East. Gulf Inject The total production capacity of WMS and WMS will exceed 28 million units of ordinary intravenous fluids, electrolytes and injectable antibiotics, 20 million units of small-volume sterile product formulas and 1.2 million units of large-volume formulas, including dialysate.”
He further added: “Gulf Inject’s solution will also be supplemented by our existing line of therapeutic injections and eye care products.”
[ad_2]
Source link